NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market yesterday that its third-quarter revenues increased 22 percent, due in part to the firm's acquisitions of Biomol and Assay Designs over the past year.

The New York-based firm said that revenues for its Enzo Life Sciences segment increased 44 percent to $12.4 million from $8.6 million year over year. Products revenues for that segment jumped 50 percent to $10.5 million, due largely to the addition of revenues from Biomol and Assay Designs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.